Company Research Report: Precision for Medicine

Company Overview

Name: Precision for Medicine

Mission of the Company: Precision for Medicine exists to solve the most complex clinical development and manufacturing challenges to bring innovative therapies to patients. Their mission is to accelerate research, development, and manufacturing while reducing costs and increasing the probability of approval.

Founded: 2012

Key People in the Company:

Chad Clark, President and Chief Operating Officer, Precision Medicine Group

Matt Arnold, President, Translational Sciences

Sofia Baig, President, Clinical Solutions

Jake Graetz, Executive Vice President, Manufacturing Solutions

Matt Grow, Chief Commercial Officer

John Khoury, Executive Vice President, Manufacturing Solutions

Tony Khoury, Executive Vice President, Manufacturing Solutions

Anshul Mangal, President, Manufacturing Solutions

Scott Marshall, PhD, President, QuartzBio

Deborah Phippard, PhD, Chief Scientific Officer

Harpreet Singh, MD, Chief Medical Officer

Headquarters: No information is available

Number of Employees: 3,500

Revenue: No information is available

Known For: Precision for Medicine is recognized for its integrated capabilities in clinical development, lab services, manufacturing, data intelligence, and commercialization. The company specializes in oncology, rare diseases, autoimmune diseases, cell therapy, and gene therapy, among others.

Products

Services Offered

1. Global CRO Services

Description: Precision for Medicine offers award-winning CRO services with deep expertise in oncology and rare disease research.

Key Features:

Over 70% of trials are in oncology.

Operations are designed to be responsive, efficient, and adaptable throughout the lifecycle of development.

2. Lab Services and Biospecimens

Description: Comprehensive lab services that support research from pre-clinical stages to post-market testing.

Key Features:

Central lab services include kit development, logistics, and sample management.

Access to over 11 million tissue, cellular, and biofluid specimens.

3. Manufacturing Solutions

Description: Partners with innovators to optimize manufacturing for advanced therapies across various biologics.

Key Features:

Over 60 facility builds and expansions in recent years.

Special focus on biologics, rare diseases, cell and gene therapies.

4. Data Intelligence

Description: Provides AI-enabled data solutions for the entire precision medicine development lifecycle.

Key Features:

Includes smart sample management, biomarker data analysis, and biostatistics.

Silo-free, unified data ecosystem.

Recent Developments

Strategic Partnerships:

November 2024: Partnership with Agena Bioscience announced at the Association for Molecular Pathology 2024 Annual Meeting & Expo.

September 2024: Strategic partnership with Navinci announced.

Acquisitions:

May 2024: Acquired Algorics to enhance clinical technologies and expand APAC presence.

Leadership Changes:

September 2024: Margaret Keegan appointed as the new CEO of Precision Medicine Group.

Technological Advancements:

November 2024: Introduction of spatial biology solutions through the PhenoCycler®-Fusion 2.0 System and new Phenocode™ Discovery IO60 Panel from Akoya Biosciences.

Conclusion

Precision for Medicine continues to enhance its global footprint and expertise in precision medicine, integrating comprehensive clinical, laboratory, manufacturing, and data intelligence capabilities. Focused on accelerating the delivery of innovative therapies, the company maintains a strong trajectory of growth through strategic partnerships, technological advancements, and leadership expansions, specifically in oncological and rare disease domains.